Scholar Rock Holding Corporation (SRRK): History, Ownership, Mission, How It Works & Makes Money

Ever heard of Scholar Rock Holding Corporation (SRRK)? This biopharmaceutical company is making waves in the treatment of serious diseases, but how exactly does it operate and generate revenue? Currently valued at $2.74 billion, with analysts predicting an 80.4% rise in stock price, understanding its unique approach to growth factor-targeted drugs could be key for investors and industry observers alike. Read on to discover its history, ownership structure, mission, and the innovative strategies that drive its financial success.

Scholar Rock Holding Corporation (SRRK) History

Scholar Rock Holding Corporation was founded to discover and develop a new class of medicines that act by selectively targeting growth factors in the disease microenvironment. Here’s a look at its origins and evolution:

Scholar Rock's Founding Timeline

Year established

Scholar Rock was established in 2012.

Original location

The company is headquartered in Cambridge, Massachusetts.

Founding team members

The founding team included individuals with expertise in growth factor biology and drug discovery. Key figures include:

• Timothy Springer: A structural immunologist from Harvard Medical School.
• Leonard Zon: A stem cell biologist from Boston Children’s Hospital and Harvard Medical School.

Initial capital/funding

Scholar Rock secured an initial Series A funding of $36 million in 2013, led by Polaris Partners and ARCH Venture Partners. This funding supported the early stages of research and development.

Scholar Rock's Evolution Milestones

Scholar Rock's Transformative Moments

• Focus on TGFβ superfamily: Scholar Rock's strategic focus on the Transforming Growth Factor beta (TGFβ) superfamily has been a cornerstone of its approach. This family of growth factors plays critical roles in various diseases, offering multiple therapeutic opportunities.
• Development of SRK-015: The development and clinical advancement of SRK-015, a selective inhibitor of myostatin activation, marks a significant milestone. This drug has shown promise in treating spinal muscular atrophy (SMA) by promoting muscle growth and strength.
• Public Offering: The company's IPO in 2017 provided substantial capital, enabling it to expand its research and development efforts. The IPO validated its technology and approach, attracting further investment and partnerships.
• Strategic Collaborations: Forming collaborations with other pharmaceutical companies and academic institutions has allowed Scholar Rock to leverage external expertise and resources. These partnerships have accelerated drug discovery and development, expanding the company's capabilities and reach.

To gain more insights into the investors behind Scholar Rock, check out this detailed analysis: Exploring Scholar Rock Holding Corporation (SRRK) Investor Profile: Who’s Buying and Why?

Scholar Rock Holding Corporation (SRRK) Ownership Structure

Scholar Rock Holding Corporation's ownership is distributed among various institutional, retail, and individual shareholders. Understanding this structure provides insights into the company's governance and strategic decision-making.

Scholar Rock Holding Corporation's Current Status

Scholar Rock Holding Corporation is a publicly traded company, listed on the NASDAQ Global Select Market under the ticker symbol SRRK. As a public entity, it is subject to regulatory oversight and reporting requirements, including those of the U.S. Securities and Exchange Commission (SEC).

Scholar Rock Holding Corporation's Ownership Breakdown

The ownership of Scholar Rock Holding Corporation is divided among institutional investors, individual shareholders, and company insiders. As of the latest available data, the breakdown is as follows:

Scholar Rock Holding Corporation's Leadership

The leadership team guides the strategic direction and operational execution of Scholar Rock Holding Corporation. Key members of the leadership team as of April 2025 include:

• David Hallal: President and Chief Executive Officer
• Yung Chyung, M.D.: Chief Medical Officer
• Gregory Carven: Chief Financial Officer

For additional insights into the company's financial standing, explore: Breaking Down Scholar Rock Holding Corporation (SRRK) Financial Health: Key Insights for Investors

Scholar Rock Holding Corporation (SRRK) Mission and Values

Scholar Rock's mission is centered on discovering and developing innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a crucial role. The company is deeply committed to scientific excellence and improving the lives of patients.

Scholar Rock's Core Purpose

Official mission statement

Scholar Rock's official mission statement is: 'To discover and develop innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a crucial role.'

• This mission reflects a focus on cutting-edge research and development.
• It emphasizes addressing severe illnesses with significant unmet medical needs.
• It highlights the importance of growth factors in disease pathology.

Vision statement

While a specific, formally declared vision statement is not explicitly available, Scholar Rock's actions and communications suggest a vision focused on:

• Becoming a leader in the field of growth factor-targeted therapies.
• Delivering transformative treatments that significantly improve patient outcomes.
• Building a sustainable and innovative biopharmaceutical company.

Company slogan/tagline

Currently, there is no widely publicized or officially declared slogan or tagline for Scholar Rock. However, considering their focus, a possible implied tagline could be:

• 'Targeting Growth Factors, Transforming Lives.'
• 'Innovation in Growth Factor Therapeutics.'

To delve deeper into Scholar Rock's guiding principles, explore: Mission Statement, Vision, & Core Values of Scholar Rock Holding Corporation (SRRK).

Scholar Rock Holding Corporation (SRRK) How It Works

Scholar Rock Holding Corporation focuses on discovering and developing medicines for the treatment of serious diseases in which protein growth factors play a crucial role. The company engineers monoclonal antibodies that selectively target growth factors to address diseases where growth factor signaling is dysregulated.

Scholar Rock's Product/Service Portfolio

Scholar Rock's Operational Framework

Scholar Rock operates through a focused research and development strategy, targeting specific growth factors with its antibody therapeutics. Key aspects of their operational framework include:

• Target Identification and Validation: Identifying disease pathways where growth factors play a significant role and validating these targets for therapeutic intervention.
• Antibody Engineering: Developing monoclonal antibodies that selectively bind to and inhibit the activation of specific growth factors.
• Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates, progressing from Phase 1 through Phase 3 trials.
• Partnerships and Collaborations: Collaborating with other pharmaceutical companies and research institutions to advance their drug development programs.

Scholar Rock's Strategic Advantages

Scholar Rock's strategic advantages stem from its innovative approach to targeting growth factors and its focus on specific disease areas. These advantages include:

• Selective Targeting: Developing highly selective antibodies allows for precise intervention in disease pathways, potentially reducing off-target effects.
• Focus on Growth Factors: Specializing in growth factor biology provides a deep understanding of these pathways, enabling the development of novel therapeutics.
• Clinical Progress: Advancing key drug candidates like Apitegromab and SRK-181 through clinical trials demonstrates the potential of their approach.

To gain more insights into the investors and stakeholders involved with Scholar Rock, check out: Exploring Scholar Rock Holding Corporation (SRRK) Investor Profile: Who’s Buying and Why?

Scholar Rock Holding Corporation (SRRK) How It Makes Money

Scholar Rock Holding Corporation primarily generates revenue through strategic collaborations and licensing agreements centered on its innovative pipeline of transforming growth factor beta (TGFβ) therapeutics.

Scholar Rock's Revenue Breakdown

As a clinical-stage biopharmaceutical company, Scholar Rock's revenue streams are primarily collaboration and licensing agreements. Given the nature of these agreements and their potential variability, a precise breakdown of revenue streams as a percentage of the total for the fiscal year 2024 isn't available without direct access to Scholar Rock's financial statements. However, we can discuss potential revenue streams based on their business model.

Scholar Rock's Business Economics

Scholar Rock operates within the biopharmaceutical industry, characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory hurdles. Their business economics are influenced by:

• R&D Expenses: A substantial portion of their expenditure is allocated to research and development, which includes preclinical studies, clinical trials, and manufacturing process development.
• Partnerships: Strategic alliances with larger pharmaceutical companies can provide significant upfront payments, milestone payments, and royalties on future sales, helping to offset R&D costs.
• Intellectual Property: Strong patent protection is crucial for maintaining market exclusivity and commanding premium pricing for their therapies.
• Regulatory Approvals: Securing regulatory approvals from agencies like the FDA is essential for commercializing their products and generating revenue.

Scholar Rock's Financial Performance

Analyzing Scholar Rock's financial performance involves assessing several key metrics that reflect the company's operational efficiency and financial stability.

• Cash Runway: Monitoring the company's cash reserves and burn rate is vital to ensure they have sufficient capital to fund ongoing research and development activities.
• Operating Expenses: Keeping track of operating expenses, including R&D and general administrative costs, helps evaluate the company's cost management strategies.
• Net Loss: As a clinical-stage company, Scholar Rock is likely to incur net losses as they invest heavily in R&D. The magnitude of these losses and the company's ability to manage them are important considerations.
• Collaboration Revenue: The revenue generated from collaboration agreements provides crucial funding for Scholar Rock's operations. The terms and structure of these agreements significantly impact their financial performance.

For more insights into Scholar Rock's financial health, you can explore: Breaking Down Scholar Rock Holding Corporation (SRRK) Financial Health: Key Insights for Investors

Scholar Rock Holding Corporation (SRRK) Market Position & Future Outlook

Scholar Rock is navigating a competitive biopharmaceutical landscape with a focus on transforming the treatment of diseases where protein growth factors are key to disease progression. Their future outlook hinges on the successful development and commercialization of their pipeline, particularly their lead candidate, apitegromab, and their ability to leverage their proprietary platform for discovering and developing novel therapeutics.

Competitive Landscape

Opportunities & Challenges

Industry Position

Scholar Rock is a clinical-stage biopharmaceutical company. The company is working to discover and develop therapies for the treatment of severe diseases in which protein growth factors play a central role. Here are some key points about their industry position:

• Focus on Growth Factors: Scholar Rock's approach of targeting growth factors differentiates them from many other companies in the biopharmaceutical space.
• Apitegromab in SMA: Apitegromab, their lead candidate, is being developed for spinal muscular atrophy (SMA).
• Early Stage: As a clinical-stage company, Scholar Rock is still in the process of proving the safety and efficacy of its drugs.

To delve deeper into the company's guiding principles, explore the Mission Statement, Vision, & Core Values of Scholar Rock Holding Corporation (SRRK).